Originally formed as Melville Biologics in NYS, then doing business as VI Technologies and then as Vitex, in June 2004, the firm acquired the assets of Panacos Pharmaceuticals - also an SBIR involved firm out of MD. In August 2005, the merged firm shifted to the name Panacos Pharmaceuticals. Firm had previously a strong focus to blood analysis. Panacos is now engaged in the discovery, development and commercialization of small molecule drugs to treat or prevent serious infectious disease. The Company has an expanding pipeline of promising anti-infective drug candidates for major markets with significant, unmet medical needs. The Company's lead antiviral product is bevirimat (PA-457), the first in a new class of drugs to treat HIV infection discovered by Panacos scientists currently in Phase 2 clinical trials.
